2022_Dec_DDL_Edinburgh_leaderboard

Otitopic

Otitopic, acquired by tobacco company Philip Morris International in 2021, was a dry powder inhalation company with expertise in formulation and drug delivery device development, including Asprihale®, a proprietary DPI aspirin formulation for cardiac indications.




Associated Companies

  Vectura  

Company Address:
10390 Santa Monica Blvd #200 Los Angeles CA 90025 United States

Phone / Contact

T: +1 877 443 8710
E: info@otitopic.com

Connect

Otitopic, acquired by tobacco company Philip Morris International in 2021, was a late-stage dry powder inhalation of aspirin company with a track record of success in pharmaceutical product drug delivery and drug device development. Asprihale® is a proprietary aspirin formulation administered via a DPI, entering the bloodstream faster than oral tablets, for cardiac indications.

Otitopic was pioneering a new class of dry-powder inhalation in the cardiovascular medicine field, based on its proprietary drug delivery platform.

Otitopic was founded in 2012.

Articles by Otitopic

Top